How IPD Can Deliver for Life Sciences

January 1, 2020

Life sciences is facing a number of disruptors: novel cell and gene therapies that will revolutionize manufacturing, drug delivery and pricing models; a battle for the best and brightest talent; political and public pressure on the price of medication as well as the implications of the fourth industrial revolution. These factors combine to make investment decisions more challenging. With life sciences firms placing an increasing focus on the most efficient use of capital and shorter delivery times, project delivery providers are striving to come up with leaner and more innovative strategies and solutions to meet these needs. Integrated Project Delivery (IPD) is one such strategy.

Spotlight

Caudex

Caudex, a division of McCann Complete Medical, is a global medical communications agency with over 25 years of industry experience, is well positioned to assist pharmaceutical firms with their education needs throughout the.

OTHER WHITEPAPERS
news image

Investing in Next-Generation Tokenization and Real-World Data to Unlock a More Precise and Complete Patient Journey

whitePaper | November 18, 2022

To realize the full potential of RWD, we must put the patient at the center and truly understand each patient’s unique circumstances over time. It’s certainly a tall order when the data we need is scattered across siloed systems and guarded by applicable and necessary patient privacy regulations.

Read More
news image

Best Practices for RIM Business Process Automation

whitePaper | December 29, 2022

Regulatory teams at life science companies are finding that effective regulatory information management (RIM) has become critical to their operations.

Read More
news image

Discovering Effective Strategies for Sales and Marketing in the Face of Reduced Access to Oncologists

whitePaper | January 15, 2023

Oncology breakthroughs are currently fueling significant growth in the market, as well as the competition between pharmaceutical brands for market share. As increasingly individualized cancer treatments become available,

Read More
news image

A Vision for the Global Generic and Biosimilar Medicines Industry

whitePaper | May 22, 2021

One of the key roles of the generic and biosimilar medicines industry is specifically to promote the widest possible access to affordable medicines with high quality, safety, and efficacy for patients globally by introducing competition into the markets. Despite the many hurdles, the generic medicines companies have clearly lived up to the challenges posed by the pandemic as it is an industry that is quick to adapt and agile in manufacturing scale-up. During the outbreak of COVID-19, this industry was providing most of the medicines needed in Intensive Care Units to ventilate critically ill COVID patients. It is also providing most of the quality medicines dispensed around the world, especially for increasingly prevalent chronic diseases and is therefore a strong contributor to health outcomes globally.

Read More
news image

Navigating the Drug Development Pipeline: Expertise for Highly Potent API Product Handling

whitePaper | July 11, 2022

The expansion in the development and manufacturing of highly potent active pharmaceutical ingredients (HPAPIs) and complex active pharmaceutical ingredients (APIs) has grown tremendously as demands in healthcare to bring newer therapies to market quicker increase.

Read More
news image

How to Choose the Right Contract Manufacturing Organisation for Your Pharmaceutical Product

whitePaper | November 21, 2022

Contract manufacturing can enhance the drug development process by creating effective processes, increasing manufacturing efficiencies, and reducing overhead costs.

Read More

Spotlight

Caudex

Caudex, a division of McCann Complete Medical, is a global medical communications agency with over 25 years of industry experience, is well positioned to assist pharmaceutical firms with their education needs throughout the.

Events